Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06662175
PHASE2/PHASE3

Role of Dexmedetomidine as Synergistic Agent

Sponsor: Lady Reading Hospital, Pakistan

View on ClinicalTrials.gov

Summary

The aim of this clinical trial is to contribute valuable insights into the role of Dexmedetomidine as a synergistic agent in prolonging subarachnoid block duration, with the overarching goal of enhancing perioperative care and surgical success rates.

Official title: Role of Dexmedetomidine as Synergistic Agent to Prolong a Subarachnoid Block Duration

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

166

Start Date

2024-11

Completion Date

2025-09

Last Updated

2024-10-28

Healthy Volunteers

No

Interventions

DRUG

Hyperbaric bupivacaine

Group A (Unexposed) will received 2 ml of intrathecal bupivacaine

DRUG

hyperbaric bupivacaine and dexmedetomidine

Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion

Locations (1)

Lady Reading Hospital Mti Peshawar Kp Pakistan

Peshawar, KPK, Pakistan